1. Report Introduction 2. Age-related Macular Degeneration (AMD) Market Overview at a Glance 2.1. Market Share Distribution of Age-related Macular Degeneration (AMD) in 2017 2.2. Market Share Distribution of Age-related Macular Degeneration (AMD) in 2027 3. Disease Background and Overview: Age-related Macular Degeneration (AMD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Age-related Macular Degeneration (AMD) in 7MM 4.3. Total Prevalent Patient Population of Age-related Macular Degeneration (AMD) in 7MM – By Countries 5. Epidemiology of Age-related Macular Degeneration (AMD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.1.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.1.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.1.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.1.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.4.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.4.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.4.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.4.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.5.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.5.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.5.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.5.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.6.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.6.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.6.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.6.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.7.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.7.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.7.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.7.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.8.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.8.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.8.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.8.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) 5.9.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) * 5.9.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) * 5.9.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD) 5.9.6. Treatable Cases of the Age-related Macular Degeneration (AMD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Age-related Macular Degeneration (AMD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Age-related Macular Degeneration (AMD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Age-related Macular Degeneration (AMD) : 7MM Market Analysis 12.1. 7MM Market Size of Age-related Macular Degeneration (AMD) 12.2. 7MM Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) 12.3. 7MM Market Sales of Age-related Macular Degeneration (AMD) by Products 13. Age-related Macular Degeneration (AMD) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Age-related Macular Degeneration (AMD) in United States 13.1.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in United States 13.1.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Age-related Macular Degeneration (AMD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Germany 13.2.1.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Age-related Macular Degeneration (AMD) in France 13.2.2.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in France 13.2.2.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Age-related Macular Degeneration (AMD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Italy 13.2.3.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Age-related Macular Degeneration (AMD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Spain 13.2.4.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Age-related Macular Degeneration (AMD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in United Kingdom 13.2.5.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Age-related Macular Degeneration (AMD) in Japan 13.3.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Japan 13.3.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM Table 2: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Table 4: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Table 5: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Table 6: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Table 7: Treatable Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Table 8: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Table 9: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Table 10: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Table 11: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Table 12: Treatable Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Table 13: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Table 14: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Table 15: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Table 16: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Table 17: Treatable Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Table 18: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Table 19: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Table 20: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Table 21: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Table 22: Treatable Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Table 23: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Table 24: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Table 25: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Table 26: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Table 27: Treatable Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Table 28: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Table 29: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Table 30: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Table 31: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Table 32: Treatable Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Table 33: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Table 34: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Table 35: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Table 36: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Table 37: Treatable Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 42:7MM- Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 43:7MM- Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 44: United States-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 45: United States-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 46: United States-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 47: Germany-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 48: Germany-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 49: Germany-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 50: France-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 51: France-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 52: France-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 53: Italy-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 54: Italy-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 55: Italy-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 56: Spain-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 57: Spain-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 58: Spain-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 59:UK-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 60:UK-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 61:UK-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 62: Japan-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Table 63: Japan-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Table 64: Japan-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 1: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Figure 4: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Figure 5: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Figure 6: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Figure 7: Treatable Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2027) Figure 8: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Figure 9: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Figure 10: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Figure 11: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Figure 12: Treatable Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2027) Figure 13: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Figure 14: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Figure 15: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Figure 16: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Figure 17: Treatable Cases of the Age-related Macular Degeneration (AMD) in France (2016-2027) Figure 18: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Figure 19: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Figure 20: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Figure 21: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Figure 22: Treatable Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2027) Figure 23: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Figure 24: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Figure 25: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Figure 26: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Figure 27: Treatable Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2027) Figure 28: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Figure 29: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Figure 30: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Figure 31: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Figure 32: Treatable Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2027) Figure 33: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Figure 34: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Figure 35: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Figure 36: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Figure 37: Treatable Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2027) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 42:7MM- Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 43:7MM- Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 44: United States-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 45: United States-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 46: United States-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 47: Germany-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 48: Germany-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 49: Germany-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 50: France-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 51: France-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 52: France-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 53: Italy-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 54: Italy-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 55: Italy-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 56: Spain-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 57: Spain-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 58: Spain-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 59:UK-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 60:UK-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 61:UK-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 62: Japan-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2027) Figure 63: Japan-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027) Figure 64: Japan-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2027)